BERKELEY, CA--(Marketwire - October 21, 2010) - Dynavax Technologies Corporation (
Presentation and discussions will focus on hepatitis B: epidemiology, unmet needs, and public/individual health Impacts, as well as the regulatory landscape and new market opportunities.
Guest speakers at the event will include:
- William Schaffner, M.D., Professor & Chairman, Department of Preventive Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine.
- Florian Schödel, M.D., PhD, formerly Merck VP, Infectious Diseases / Vaccines Clinical Research.
- Peter Patriarca, M.D., formerly, FDA Director, Division of Viral Products, Office of Vaccines Research & Review in the Center for Biologics Evaluation & Research (CBER).
- Stanley Plotkin, M.D., Emeritus Professor of Pediatrics and Microbiology, University of Pennsylvania.
Presentations by Dynavax's Dr. Tyler Martin, President and Chief Medical Officer; Dr. Robert Coffman, Chief Scientific Officer; Brant Biehn, Chief Commercial Officer; and Dr. Dino Dina, Chief Executive Officer will also be broadcast. To access the live webcast and the subsequent archived audio recording of the presentation, please log onto Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
About Dynavax
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit www.dynavax.com.
Contact Information:
Contact:
Shari Annes
Investor Relations
510-665-7211